GLA
OVID icon

Great Lakes Advisors’s Ovid Therapeutics OVID Stock Holding History

Great Lakes Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,196
Closed -$49K – 747
2021
Q4 		$49K Sell
15,196
-1,185
-7% -$4.06K ﹤0.01% 694
2021
Q3 		$55K Sell
16,381
-95
-0.6% -$346 ﹤0.01% 680
2021
Q2 		$64K Sell
16,476
-417
-2% -$1.65K ﹤0.01% 694
2021
Q1 		$68K Buy
+16,893
New +$56.1K ﹤0.01% 686

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Great Lakes Advisors's OVID Position: Q1 2022 in Review

Great Lakes Advisors sold out of Ovid Therapeutics (OVID) in Q1 2022, closing a stake of 15,196 shares — an estimated $49K sold.

Great Lakes Advisors first reported a position in OVID in Q1 2021 and held it in 4 quarters. The position peaked at $68K in Q1 2021. 62 funds tracked by Wall St. Rank hold OVID as of Q1 2022.

  • Great Lakes Advisors reported no remaining Ovid Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Great Lakes Advisors sold 15,196 Ovid Therapeutics shares in Q1 2022, an estimated $49K.
  • Great Lakes Advisors first reported a position in Ovid Therapeutics in Q1 2021 and held it in 4 quarters.
  • Great Lakes Advisors's Ovid Therapeutics position peaked at $68K in Q1 2021.
  • 62 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2022.

Based on Great Lakes Advisors's 13F filing for Q1 2022, filed 6 May 2022.